NOK 4.53
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. The company was founded in 2017 and is headquartered in Oslo, Norway.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA, overp
Data is available to registered users only
Target Price
The average target price of TRMED.OL is 3.5 and suggests 23% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to
Data is available to registered users only